| review article | Q7318358 |
| scholarly article | Q13442814 |
| P356 | DOI | 10.1080/1042819031000079087 |
| P698 | PubMed publication ID | 12952218 |
| P2093 | author name string | Françoise Vuillier | |
| Guillaume Dighiero | |||
| P2860 | cites work | Dendritic cells use macropinocytosis and the mannose receptor to concentrate macromolecules in the major histocompatibility complex class II compartment: downregulation by cytokines and bacterial products | Q24678867 |
| Dendritic cells and the control of immunity | Q27860918 | ||
| Genomic aberrations and survival in chronic lymphocytic leukemia | Q28141442 | ||
| B-cell chronic lymphocytic leukemia: a bird of a different feather | Q28142747 | ||
| Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX | Q28219302 | ||
| Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha | Q28251443 | ||
| Generation in vitro of B-cell chronic lymphocytic leukaemia-proliferative and specific HLA class-II-restricted cytotoxic T-cell responses using autologous dendritic cells pulsed with tumour cell lysate | Q28362580 | ||
| Immunobiology of dendritic cells | Q29547465 | ||
| Update on the biology of chronic lymphocytic leukemia | Q33845180 | ||
| Dendritic cells in cancer immunotherapy | Q33932695 | ||
| A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis | Q34282319 | ||
| Sensing pathogens and tuning immune responses | Q34308011 | ||
| The use of dendritic cells in cancer therapy | Q34571978 | ||
| Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? | Q34605294 | ||
| Exploiting dendritic cells to improve vaccine efficacy | Q34691785 | ||
| Chlorambucil in indolent chronic lymphocytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia | Q34747331 | ||
| Dendritic cells at the host-pathogen interface. | Q34765258 | ||
| Induction of antigen-specific T cell anergy: An early event in the course of tumor progression | Q35798927 | ||
| Proliferating dendritic cell progenitors in human blood | Q36363279 | ||
| CD34+ hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF+TNF alpha | Q36367113 | ||
| Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy | Q40701090 | ||
| Origin, maturation and antigen presenting function of dendritic cells. | Q40906220 | ||
| Mechanisms of antigen uptake for presentation | Q41102979 | ||
| Control of T lymphocyte signal transduction through clonal anergy | Q41257500 | ||
| The triterpenoid CDDO induces apoptosis in refractory CLL B cells | Q44155427 | ||
| Autologous T lymphocytes may specifically recognize leukaemic B cells in patients with chronic lymphocytic leukaemia | Q45873210 | ||
| Dendritic cells in patients with non-progressive B-chronic lymphocytic leukaemia have a normal functional capability but abnormal cytokine pattern | Q45881367 | ||
| Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells | Q46578425 | ||
| Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer | Q47784815 | ||
| Idiotope-specific T cell clones that recognize syngeneic immunoglobulin fragments in the context of class II molecules | Q57275645 | ||
| Immunoglobulin framework-derived peptides function as cytotoxic T-cell epitopes commonly expressed in B-cell malignancies | Q57556550 | ||
| Novel flow-cytometric analysis based on BCD5+ subpopulations for the evaluation of minimal residual disease in chronic lymphocytic leukaemia | Q58041763 | ||
| Idiotype-pulsed dendritic cells are able to induce antitumoral cytotoxic CD8 cells in chronic lymphocytic leukaemia | Q58484362 | ||
| Vaccination of multiple myeloma patients with idiotype-pulsed dendritic cells: immunological and clinical aspects | Q73738443 | ||
| T-cell responses against chronic lymphocytic leukemia cells: implications for immunotherapy | Q74314281 | ||
| Defective assembly of the B-cell receptor chains accounts for its low expression in B-chronic lymphocytic leukaemia | Q74673953 | ||
| Transplant-lite: induction of graft-versus-malignancy using fludarabine-based nonablative chemotherapy and allogeneic blood progenitor-cell transplantation as treatment for lymphoid malignancies | Q77093417 | ||
| Induction of cytotoxic T-cell responses against immunoglobulin V region-derived peptides modified at human leukocyte antigen-A2 binding residues | Q77136377 | ||
| Functional monocyte-derived dendritic cells can be generated in chronic lymphocytic leukaemia | Q77637141 | ||
| Idiotypic protein-pulsed dendritic cell vaccination in multiple myeloma | Q78202930 | ||
| P433 | issue | 8 | |
| P921 | main subject | dendritic cell | Q506253 |
| lymphocyte | Q715347 | ||
| P304 | page(s) | 1267-1273 | |
| P577 | publication date | 2003-08-01 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Monocyte-derived dendritic cells in chronic lymphocytic leukemia | |
| P478 | volume | 44 |
| Q34521343 | Dendritic cells from chronic lymphocytic leukemia patients are normal regardless of Ig V gene mutation status. |
| Q79967042 | Dendritic cells in cancer immunotherapy |
| Q31104353 | The potential of gene transfer into primary B-CLL cells using recombinant virus vectors |
| Q34011555 | Type 1-polarized dendritic cells loaded with autologous tumor are a potent immunogen against chronic lymphocytic leukemia |
Search more.